A recent report by EY and ASSOCHAM recommends capital subsidies of up to 50% for the bioplastics sector in India, aiming to offset high production costs and align with the BioE3 policy's goals of promoting bio-manufacturing and achieving net-zero emissions. The report suggests reducing GST on bioplastics to 12% and encourages state governments to provide additional incentives, such as interest subvention and power rebates. It advocates for a strong regulatory framework, including Quality Control Orders and import restrictions to support domestic production. Meanwhile, the BioE3 policy, launched in August 2024, emphasizes biotechnology in various sectors, including lab-made dairy, which faces backlash from traditional dairy farmers concerned about market disruption. With significant investments in research and clean energy initiatives, the Indian government aims to enhance bio-based product quality and production while fostering entrepreneurship in the biotechnology sector. However, the acceptance of lab-made dairy products remains uncertain among consumers who value traditional milk sources.